BOSTON — A sustained-release bimatoprost drug delivery platform shows promise in the treatment of ocular hypertension and open-angle glaucoma, according to a poster at the American Society of Cataract and Refractive Surgery meeting.
Gregory J. Katz, MDABO, and co-authors presented 12-month interim safety and efficacy data from a first-in-human study in which 23 eyes were implanted with the SpyGlass Pharma IOL-based drug delivery platform with bimatoprost, at doses of 75 µg, 150 µg or 300 µg, at the time of cataract surgery.
A statistically significant IOP reduction was